Category: Uncategorized

  • Are You Giving Away Control of Your Product in Vietnam?

    Are You Giving Away Control of Your Product in Vietnam?

    Many manufacturers let distributors hold their Market Authorization (MA) /license. While convenient, this can limit your control, flexibility, and long-term strategy.

    Strategic Separation = Market Power
    By appointing an independent third-party MAH (like Medflash), you keep regulatory ownership separate from sales. This unlocks:

    1.  Market Access & Distribution Flexibility
    – Unconstrained Distributor Selection: Appoint multiple distributors based on geography or market segment without tying your license to one partner.
    – Easy Distributor Change: Replace underperforming distributors without triggering complex re-registration.
    – Pricing Control: Maintain consistent pricing strategy across all channels.

    2. Risk Mitigation & Confidentiality
    – Insulation from Distributor Failure: Your license remains safe even if a distributor exits or faces compliance issues.
    – IP Protection: Share sensitive regulatory files only with a trusted MAH, not multiple sales-focused entities.
    – Centralized Regulatory Intelligence: Get timely updates on law changes from your dedicated regulatory partner.

    3. Global Strategy Alignment
    – Consistency: Align Vietnam compliance with global QMS updates and documentation.
    – Neutral Representation: Avoid conflicts between competing distributors.
    – Bottom line: This model is regulatory outsourcing that gives you market agility, legal insulation, and full control over your brand in Vietnam.

     Are you ready to take control of your regulatory strategy in Vietnam? Let’s connect and discuss how Medflash can help.

  • VIETNAM: The Medical Tourism Plan is a MedTech Investment

    VIETNAM: The Medical Tourism Plan is a MedTech Investment

    Vietnam is strategically moving to put medical tourism on the map via a new Ministry of Health plan (2025–2030). This isn’t just a service push—it’s the clearest policy signal for accelerated medical device sector growth you can get.

    Why Global MD Firms Must Look at Vietnam NOW:

    • Policy Mandate: The new plan requires key healthcare hubs (Hanoi, HCMC, Da Nang) to achieve international standards (e.g., JCI). This quality drive creates immediate demand for compliant technology.
    • Cost & Capability: Vietnam offers high-quality care at 30–50% lower costs than regional peers, with proven expertise in high-demand areas (Cardiology, Orthopedics, IVF).
    • Massive Equipment Upgrade: Achieving JCI standardization requires a complete, accelerated overhaul of all medical technology. This creates a non-negotiable, long-term purchasing runway for certified foreign MD manufacturers.

    Vietnam has the critical ingredients: low cost, high capability, and now, a strong policy push for international standards.

    DON’T MISS THIS WINDOW

    Stop waiting for the next signal. The time to establish your strategic manufacturing or distribution footprint is NOW.

  • Three strategic pathways to navigate Vietnam’s Medical Device Market

    Three strategic pathways to navigate Vietnam’s Medical Device Market

    Vietnam’s medical device market is booming—expected to reach nearly US$2.5 billion by 2030, with 90–95% of equipment imported. As the MoH tightens regulations under Decree 98/2021 and its amendments, the path to market access is more structured than ever.

    1. Establish a Legal Entity (Subsidiary, Representative Office)

    • Eligible to hold device registrations (MA license) + registration holder status.
    • Requires local investment certificate and business license.
    • High control + independence in pricing, strategy, supply chain—but costly setup, operational burden, QMS localization.

    2. Appoint a Local Distributor (Importer)

    • Distributor holds import license, manages MA filing and ministry liaison.
    • Minimal regulatory setup for foreign company, leverages distributor’s local networks.
    • A trade-off: distributor usually owns the MA, potentially reducing your control over pricing and partnerships.

    3. Engage an Independent Third-Party Authorized Representative

    • Local agent (Medflash) holds marketing authorization in your name, acts as official liaison.
    • Switch distributors freely without re-registering products.
    • Manages dossier submission, post-market surveillance, renewals, recalls.
    • Flexible & cost-effective—ideal for export-phased strategies.

    Strategic Considerations

    • Large-Tier players: May prefer full control via local entity.
    • Export-minded or flexible portfolios: Independent AR keeps you agile and responsive.
    • Low-volume/niche launches: Go-to-market with distributor support offers speed.
    • Long-term presence: A legal entity signals commitment; greater control over procurement.

    Looking to enter Vietnam’s medical device market without the hassle? Let Medflash be your trusted MA holder and regulatory partner.

  • EuroCham Vietnam’s Whitebook 2025: A Roadmap for Sustainable Growth Amid Global Challenges

    EuroCham Vietnam’s Whitebook 2025: A Roadmap for Sustainable Growth Amid Global Challenges

    EuroCham’s 2025 Whitebook focuses on:

    • Charting Vietnam’s green and sustainable economic path.
    • Highlighting issues affecting European businesses in Vietnam.
    • Providing recommendations to the Vietnamese government.
    • Promoting administrative reform and the twin transition towards a green and sustainable economy.
    • Marking the fifth anniversary of the EU-Vietnam Free Trade Agreement (EVFTA).

    Strengthening EU-Vietnam Ties:

    As the EU-Vietnam Free Trade Agreement (EVFTA) nears its fifth anniversary, the Whitebook underscores its impact—EU-Vietnam trade grew 16% in 2024, surpassing $68 billion. EuroCham Chairman Bruno Jaspaert highlighted Vietnam’s “bamboo diplomacy” as key to building long-term economic alliances, urging policymakers to act swiftly to leverage Vietnam’s strategic position as an EU gateway to ASEAN

    Call to Action:

    Despite challenges like geopolitical volatility and newly imposed U.S. tariffs, EuroCham remains optimistic. The Whitebook serves as a practical toolkit for Vietnamese policymakers and businesses to address inefficiencies, boost investor confidence, and ensure sustainable prosperity.

    Link for WhiteBook 2025

  • Navigating Borderline Medical Devices: Global Regulatory Insights

    Navigating Borderline Medical Devices: Global Regulatory Insights

    Borderline medical devices—products that blur the lines between medical devices, medicinal products, cosmetics, or other categories—pose unique challenges for manufacturers and regulators. Regulatory authorities worldwide provide guidance, manuals, and case studies to clarify classifications, helping ensure compliance and market access. Below, we summarize key resources from major regions and countries, with links to access these critical documents for navigating borderline medical device classifications.

    European Union (EU): Comprehensive Classification Manual

    The European Commission’s Manual on Borderline and Classification in the Community Regulatory Framework for Medical Devices, published by the Medical Devices Coordination Group (MDCG), is a cornerstone resource. Updated regularly, it includes case studies on products like AED storage units (Class I medical device), lubricants for vaginal dryness (Class IIa), and riboflavin solutions (medicinal product). This manual, aligned with Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR), offers non-binding but consensus-driven guidance.

    United Kingdom (UK): MHRA Borderline Determinations

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) provides the “Borderlines with medical devices and other products in Great Britain” document, detailing classifications under the UK Medical Device Regulations 2002. Examples include ethyl chloride sprays (active medical devices) and gym equipment with heart rate monitors (non-medical devices). The MHRA’s Annex A lists specific determinations, offering clarity for manufacturers in Great Britain.

    ASEAN Region: Harmonized Classification Efforts

    The ASEAN Medical Device Directive (AMDD) guides classification across member states like Singapore and Malaysia. While no centralized list exists, guidance addresses borderline products like hand sanitizers (biocides vs. medical devices) and herbal syrups (food supplements vs. devices). National authorities provide specific insights.

    United States (US): FDA Classification Resources

    The U.S. Food and Drug Administration (FDA) addresses borderline devices through guidance documents and its Product Classification Database, without a dedicated list. Software as a medical device (SaMD), combination products like drug-eluting stents, and cosmetic lasers are common borderline cases. Manufacturers can request a Request for Designation (RFD) for clarity via the Office of Combination Products (OCP).

    Australia: Rules for boundary and combination products

    The Therapeutic Goods Administration (TGA) regulates medical devices under the Therapeutic Goods Act 1989, with guidance on borderline products distinguishing devices from medicines or cosmetics.

    Brazil: requests for classification of border products

    Brazil’s National Health Surveillance Agency (ANVISA) oversees medical devices under resolutions like RDC 751/2022, with borderline products evaluated based on specific procedures. Manufacturers can request for classification of border products.

    Canada: Health Canada’s Case-by-Case Approach

    Health Canada regulates medical devices under the Medical Devices Regulations, addressing borderline cases through guidance documents like “Classification of products at the drug-medical device interface”, “Classification of Products at the Cosmetic-Drug Interface”. Health Canada evaluates products case-by-case, focusing on intended purpose and risk.

    Defining the regulatory status of borderline products requires careful consideration of intended purpose, mechanism of action, and specific definitions within each jurisdiction. Consulting official guidance and classification rules is a vital first step globally.

    Navigating these borderline issues can be complex. Don’t hesitate to seek expert regulatory advice to ensure you’re on the right path!